DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking

Not Applicable

Not yet recruiting

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Procedure: Biospecimen Collection
Behavioral: Smoking Cessation Intervention
Other: Survey Administration

First Posted Date: 2023-11-24

Last Posted Date: 2024-12-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 776

Registration Number: NCT06145763

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1

Withdrawn

Conditions: Prostate Carcinoma
Stage III Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8
Prostate Small Cell Neuroendocrine Carcinoma

Interventions: Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Bridge Therapy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Multigated Acquisition Scan
Biological: T-cell Receptor-engineered T-cells
Procedure: X-Ray Imaging

First Posted Date: 2023-10-23

Last Posted Date: 2025-04-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06094842

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm

Interventions: Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Biological: T-cell Receptor-engineered T-cells

First Posted Date: 2023-09-21

Last Posted Date: 2025-04-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 5

Registration Number: NCT06043713

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Procedure: Echocardiography
Drug: Fludarabine
Drug: Granulocyte Colony-Stimulating Factor
Drug: Idarubicin
Procedure: Multigated Acquisition Scan
Drug: Pivekimab Sunirine

First Posted Date: 2023-09-13

Last Posted Date: 2025-02-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06034470

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Phase 2

Recruiting

Conditions: Acute Graft Versus Host Disease
Hematopoietic and Lymphatic System Neoplasm

Interventions: Drug: Fecal Microbiota Transplantation Capsule
Drug: Placebo

First Posted Date: 2023-09-07

Last Posted Date: 2025-03-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 138

Registration Number: NCT06026371

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma

Phase 1

Recruiting

Conditions: Retroperitoneal Sarcoma

Interventions: Drug: Abemaciclib
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Procedure: Therapeutic Surgical Procedure

First Posted Date: 2023-09-06

Last Posted Date: 2025-03-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT06025747

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Phase 2

Recruiting

Conditions: Acute Leukemia of Ambiguous Lineage
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Hematopoietic and Lymphatic System Neoplasm
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma
Chronic Myeloid Leukemia, BCR-ABL1 Positive

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Drug: Cyclophosphamide
Drug: Cyclosporine
Procedure: Diagnostic Imaging
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Procedure: Multigated Acquisition Scan
Drug: Mycophenolate Mofetil
Other: Survey Administration
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2023-08-28

Last Posted Date: 2025-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 54

Registration Number: NCT06013423

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Phase 2

Recruiting

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Belumosudil
Procedure: Biospecimen Collection
Other: Electronic Health Record Review
Drug: Placebo Administration

First Posted Date: 2023-08-18

Last Posted Date: 2025-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 82

Registration Number: NCT05996627

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Mass General Cancer Center, Boston, Massachusetts, United States

and more 2 locations

IVIG for Infection Prevention After CAR-T-Cell Therapy

Phase 2

Recruiting

Conditions: Hematologic Malignancies

Interventions: Biological: Immune Globulin Infusion (Human), 10% Solution
Biological: Anti-CD19 CAR T Cells Preparation
Other: Saline
Procedure: Biospecimen Collection
Other: Survey Administration
Other: Electronic Health Record Review

First Posted Date: 2023-07-19

Last Posted Date: 2025-04-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT05952804

Locations: 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 2 locations

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Phase 1

Withdrawn

Conditions: Refractory Mantle Cell Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Mantle Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Interferon Beta-1A
Procedure: X-Ray Imaging
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Lumbar Puncture
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2023-07-07

Last Posted Date: 2024-07-12

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT05936229

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy